

Active Astellas EAPs (last updated: April 11th, 2017)

Code Number/ Generic name	Brief Protocol Title	Area	ClinicalTrials.gov Identifier
ASP2215/ Gilteritinib	Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	US	NCT03070093